Siemens Healthcare is the first company to announce a comprehensive amyloid imaging solution by combining reliable PET radiopharmaceutical manufacturing and distribution with innovative hardware technologies and software1 for PET/CT imaging of amyloid plaques—one of the necessary pathological features of Alzheimer’s disease3,4,5—in the living brain.
For the first time in clinical practice, physicians can utilize PET imaging to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline.
Siemens' PETNET Solutions operates the largest global network of PET/CT radiopharmaceutical manufacturing facilities and dispensing nuclear pharmacies offering access to the largest portfolio of PET radiopharmaceuticals throughout the world. Siemens' PETNET Solutions has standardized equipment and procedures to ensure consistent products from all sites throughout the world. As such, every dose meets the required standards for product quality and purity, from production to labeled expiration time, enabling reliable distribution of imaging biomarkers. With this, Siemens' PETNET Solutions is able to offer imaging centers and hospitals a high level of delivery reliability, up to 96 percent, adding to your confidence in being able to scan patients as scheduled.
Quantitative Accuracy with Biograph mCT
The Biograph™ mCT PET/CT family offers you the highest image quality,6 with the market's leading 95 mm3 volumetric resolution,7 and quantifiable results that are accurate. syngo®.PET Amyloid Plaque1 is Siemens' proprietary quantification software that quantifies amyloid plaque deposits in the brain.
Beyond the Foundation
Siemens has a recognized portfolio of programs to help customers establish and grow their PET imaging offerings and provide new services to their communities starting with a personalized implementation plan and continuing with workflow, clinical and marketing support.
1 syngo.PET Amyloid Plaque is intended for use only with approved amyloid radiopharmaceuticals in the country of use. Users should review the drug labeling for approved uses.
2Alzheimer's Association, 2013 Alzheimer's Disease Facts and Figures, Alzheimer's & Dementia, Volume 9, Issue 2.
3 Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging–Alzheimer’s Association Guidelines for the Neuropathologic Assessment of Alzheimer’s Disease. Alzheimers Dement. 2012;8:1-13.
4 Mirra SS, Heyman A, McKeel D, et al; and participating CERAD neuropathologists. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD): Part II: Standardization of the Neuropathologic Assessment of Alzheimer’s Disease. Neurology. 1991;41(4):479–486.
5 Thies W, Bleiler L; Alzheimer’s Association. Alzheimer’s Association Report: 2012 Alzheimer’s Disease Facts and Figures. Alzheimers Dement. 2012;8:131-168.
6 2011 PET Image Quality Survey conducted in the U.S. and Europe as a custom study by IMV, a neutral third party market research company.
7 Based on volumetric resolution available in competitive literature for systems greater than 70 cm bore size. Data on file.